Relative Bioavailability of Phase II and Phase III Formulations of AZD0530

A Phase I, Randomised, Open-Label, Cross-Over, Single Centre Study in Healthy Volunteers to Determine the Relative Bioavailability of the Phase III Tablet Formulation to the Phase II Tablet Formulation of AZD0530

The aim of the study is to compare how different formulations of AZD0530 are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Inclusion Criteria:

• Female subjects must be of Non- child-bearing potential
• Body mass index between 19 and 30 kg/m2 and weigh between 50-100 kg

Exclusion Criteria:

• Presence of any clinically significant illness
• Abnormal vital signs
• History of any conditions that may put the subject at risk by participating in the study
• Participation in another clinical study.